Bioline RX (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $4.00 price objective on Bioline RX (NASDAQ:BLRX) in a report published on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Bioline RX from a hold rating to a sell rating in a report on Thursday, August 24th. Zacks Investment Research upgraded shares of Bioline RX from a sell rating to a hold rating in a report on Thursday, September 7th. Oppenheimer restated a buy rating and issued a $3.00 price objective on shares of Bioline RX in a report on Tuesday, September 12th. Finally, Maxim Group set a $3.00 price objective on shares of Bioline RX and gave the company a buy rating in a report on Monday, December 4th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $2.88.

Bioline RX (BLRX) traded up $0.03 during trading on Thursday, hitting $1.12. 1,410,100 shares of the stock were exchanged, compared to its average volume of 489,670. Bioline RX has a twelve month low of $0.80 and a twelve month high of $1.38.

An institutional investor recently bought a new position in Bioline RX stock. Renaissance Technologies LLC purchased a new position in shares of Bioline RX Ltd (NASDAQ:BLRX) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 131,480 shares of the biotechnology company’s stock, valued at approximately $126,000. Renaissance Technologies LLC owned approximately 0.21% of Bioline RX as of its most recent SEC filing. 37.03% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Bioline RX (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/22/bioline-rx-blrx-given-a-4-00-price-target-by-hc-wainwright-analysts.html.

Bioline RX Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for Bioline RX (NASDAQ:BLRX)

Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit